Subjects: TDS, FVT
Sigilon Therapeutics to Present at the 16th Annual BIO Investor Forum in San Francisco
CAMBRIDGE, Mass., Oct. 12, 2017 /PRNewswire/ -- Sigilon Therapeutics, a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants, today announced that James Watson, Chief Business Officer, will present at the BIO Investor Forum to be held Oct. 17-18, 2017. Presentation details are as follows:
|
Date: |
Tuesday, Oct. 17, 2017 |
|
Time: |
9 a.m. PDT |
|
Location: |
Westin St. Francis Hotel, San Francisco |
About Sigilon Therapeutics
Sigilon Therapeutics is a biopharmaceutical company that discovers and develops immune-privileged living therapeutic implants for the treatment of chronic diseases. Treatments based on Sigilon Therapeutics' technology platform include cell implants that act as responsive "living therapeutics," providing more natural control for diseases that are currently treated with intermittent injection or infusion. Initial areas of focus include hematologic, enzyme deficiency, endocrine and metabolic disorders. More natural control would restore health and free patients from the need for therapies that are disruptive to quality of life.
For more information please visit www.sigilon.com or follow us on Twitter at https://twitter.com/Sigilon_Inc.
SOURCE Sigilon Therapeutics
These press releases may also interest you
|
News published on and distributed by:
